RESUMO
Modulation of the metabotropic glutamate type 2 (mGlu2) receptor is considered a promising target for the treatment of central nervous system diseases such as schizophrenia. Here, we describe the pharmacological properties of the novel mGlu2 receptor positive allosteric modulator (PAM) 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) and its radioligand [(3)H]JNJ-40068782. In guanosine 5'-O-(3-[(35)S]thio)triphosphate binding, JNJ-40068782 produced a leftward and upward shift in the glutamate concentration-effect curve at human recombinant mGlu2 receptors. The EC50 of JNJ-40068782 for potentiation of an EC20-equivalent concentration of glutamate was 143 nM. Although JNJ-40068782 did not affect binding of the orthosteric antagonist [(3)H]2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid (LY-341495), it did potentiate the binding of the agonist [(3)H](2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine (DCG-IV), demonstrating that it can allosterically affect binding at the agonist recognition site. The binding of [(3)H]JNJ-40068782 to human recombinant mGlu2 receptors in Chinese hamster ovary cells and rat brain receptors was saturable with a KD of â¼10 nM. In rat brain, the anatomic distribution of [(3)H]JNJ-40068782 was consistent with mGlu2 expression previously described and was most abundant in cortex and hippocampus. The ability of structurally unrelated PAMs to displace [(3)H]JNJ-40068782 suggests that PAMs may bind to common determinants within the same site. It is noteworthy that agonists also increased the binding affinity of [(3)H]JNJ-40068782. JNJ-40068782 influenced rat sleep-wake organization by decreasing rapid eye movement sleep with a lowest active dose of 3 mg/kg PO. In mice, JNJ-40068782 reversed phencyclidine-induced hyperlocomotion with an ED50 of 5.7 mg/kg s.c. Collectively, the present data demonstrate that JNJ-40068782 has utility in investigating the potential of mGlu2 modulation for the treatment of diseases characterized by disturbed glutamatergic signaling and highlight the value of [(3)H]JNJ-40068782 in exploring allosteric binding.
Assuntos
Fármacos Atuantes sobre Aminoácidos Excitatórios/farmacologia , Piperidinas/farmacologia , Piridonas/farmacologia , Receptores de Glutamato Metabotrópico/efeitos dos fármacos , Aminoácidos/metabolismo , Animais , Autorradiografia , Ligação Competitiva/efeitos dos fármacos , Química Encefálica , Células CHO , Cálcio/metabolismo , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Cricetinae , Cricetulus , Ciclopropanos/metabolismo , Agonistas de Aminoácidos Excitatórios/metabolismo , Glicina/análogos & derivados , Glicina/metabolismo , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Marcação por Isótopo , Ligantes , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Sono/efeitos dos fármacos , Trítio , Xantenos/metabolismoRESUMO
A series of N-propyl-8-chloro-6-substituted isoquinolones was identified as positive allosteric modulators of metabotropic glutamate receptor 2 (mGluR2 PAM) via high throughput screening (HTS). The subsequent synthesis and initial SAR exploration that led to the identification of compound 28 is described.
Assuntos
Piridinas/síntese química , Quinolonas/química , Receptores de Glutamato Metabotrópico/química , Regulação Alostérica , Ensaios de Triagem em Larga Escala , Humanos , Microssomos Hepáticos/metabolismo , Piridinas/química , Piridinas/farmacologia , Quinolonas/síntese química , Quinolonas/farmacologia , Receptores de Glutamato Metabotrópico/metabolismo , Relação Estrutura-AtividadeRESUMO
Imidazo[1,2-a]pyridines were identified via their shape and electrostatic similarity as novel positive allosteric modulators of the metabotropic glutamate 2 receptor. The subsequent synthesis and SAR are described. Potent, selective and metabolically stable compounds were found representing a promising avenue for current further studies.
Assuntos
Imidazóis/química , Piridinas/química , Piridonas/química , Receptores de Glutamato Metabotrópico/química , Regulação Alostérica , Animais , Humanos , Microssomos Hepáticos/metabolismo , Piridinas/síntese química , Piridinas/farmacologia , Ratos , Receptores de Glutamato Metabotrópico/metabolismo , Eletricidade Estática , Relação Estrutura-AtividadeRESUMO
Starting from two weak mGlu2 receptor positive allosteric modulator (PAM) HTS hits (4 and 5), a molecular hybridization strategy resulted in the identification of a novel spiro-oxindole piperidine series with improved activity and metabolic stability. Scaffold hopping around the spiro-oxindole core identified the 3-(azetidin-3-yl)-1H-benzimidazol-2-one as bioisoster. Medicinal chemistry optimization of these two novel chemotypes resulted in the identification of potent, selective, orally bioavailable, and brain penetrant mGluR2 PAMs.
RESUMO
INTRODUCTION: Positive allosteric modulation of mGlu2 has attracted much interest as an alternative approach to classical orthosteric receptor activation. Two mGlu2 PAMS have advanced into the clinic. The results obtained in schizophrenia and MDD phase 2 clinical trials have tempered the high expectations put on selective mGlu2 receptor activation for treating these conditions; nevertheless, the search for novel therapeutic indications and novel chemotypes continues to be an active field of research. AREAS COVERED: 2013-2018 patent literature on mGlu2 receptor PAMs. EXPERT OPINION: After a decade of intensive research, the mGlu2 PAM field has seen a deceleration in the last five years. Negative phase 2 schizophrenia clinical trials with JNJ-40411813 and AZD8529 seem to have tempered the high expectations of the scientific community on the utility of mGlu2 PAMs for the treatment of schizophrenia. Nevertheless, novel therapeutic indications continue to be explored and AZD8529 is currently in a phase 2 study for smoking cessation. The advances in medicinal chemistry and in pharmacology, with novel indications such as epilepsy, have set the stage in the field of mGlu2 receptor PAMs. Ongoing preclinical and clinical studies will contribute to define their optimal therapeutic indication and potential to become novel therapeutic agents.
Assuntos
Indóis/uso terapêutico , Oxidiazóis/uso terapêutico , Piperidinas/uso terapêutico , Piridonas/uso terapêutico , Receptores de Glutamato Metabotrópico/efeitos dos fármacos , Regulação Alostérica/efeitos dos fármacos , Animais , Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Maior/fisiopatologia , Humanos , Indóis/farmacologia , Oxidiazóis/farmacologia , Patentes como Assunto , Piperidinas/farmacologia , Piridonas/farmacologia , Receptores de Glutamato Metabotrópico/metabolismo , Esquizofrenia/tratamento farmacológico , Esquizofrenia/fisiopatologiaRESUMO
The metabotropic glutamate 7 (mGlu7) receptor belongs to the group III of mGlu receptors. Since the mGlu7 receptor can control excitatory neurotransmission in the hippocampus and cortex, modulation of the receptor may have therapeutic benefit in several CNS diseases. However, mGlu7 remains relatively unexplored among the eight known mGlu receptors partly because of the limited availability of tool compounds to interrogate its potential therapeutic utility. Here we report the discovery of a new class of mGlu7 allosteric agonists. Hits originating from virtual screening were followed up with further analogue searching and screening, leading to a novel series of mGlu7 allosteric agonists. Guided by docking into a structural model of the mGlu7 receptor the initial hit 5 was successfully optimized to analogues with comparable potencies and more attractive drug-like attributes than AMN082.
Assuntos
Agonistas de Aminoácidos Excitatórios/química , Agonistas de Aminoácidos Excitatórios/farmacologia , Simulação de Acoplamento Molecular/métodos , Receptores de Glutamato Metabotrópico/agonistas , Receptores de Glutamato Metabotrópico/química , Regulação Alostérica/efeitos dos fármacos , Regulação Alostérica/fisiologia , Animais , Células CHO , Cricetinae , Cricetulus , Humanos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Ratos , Receptores de Glutamato Metabotrópico/metabolismoRESUMO
Covalent labeling of G protein-coupled receptors (GPCRs) by small molecules is a powerful approach to understand binding modes, mechanism of action, pharmacology, and even facilitate structure elucidation. We report the first covalent positive allosteric modulator (PAM) for a class C GPCR, the mGlu2 receptor. Three putatively covalent mGlu2 PAMs were designed and synthesized. Pharmacological characterization identified 2 to bind the receptor covalently. Computational modeling combined with receptor mutagenesis revealed T7917.29×30 as the likely position of covalent interaction. We show how this covalent ligand can be used to characterize the PAM binding mode and that it is a valuable tool compound in studying receptor function and binding kinetics. Our findings advance the understanding of the mGlu2 PAM interaction and suggest that 2 is a valuable probe for further structural and chemical biology approaches.
Assuntos
Desenho de Fármacos , Receptores de Glutamato Metabotrópico/química , Regulação Alostérica , Sítio Alostérico , Humanos , Cinética , Ligantes , Simulação de Acoplamento Molecular , Mutagênese , Estrutura Terciária de Proteína , Piridinas/síntese química , Piridinas/química , Piridinas/metabolismo , Receptores de Glutamato Metabotrópico/genética , Receptores de Glutamato Metabotrópico/metabolismoRESUMO
We report the synthesis and biological evaluation of a series of 7-aryl-1,2,4-triazolo[4,3-a]pyridines with mGlu2 positive allosteric modulator (PAM) activity and affinity. Besides traditional in vitro parameters of potency and affinity, kinetic parameters kon, koff and residence time (RT) were determined. The PAMs showed various kinetic profiles; kon values ranged over 2 orders of magnitude, whereas RT values were within a 10-fold range. Association rate constant kon was linearly correlated to affinity. Evaluation of a short, medium, and long RT compound in a label-free assay indicated a correlation between RT and functional effect. The effects of long RT compound 9 on sleep-wake states indicated long RT was translated into sustained inhibition of rapid eye movement (REM) in vivo. These results show that affinity-only driven selection would have resulted in mGlu2 PAMs with high values for kon but not necessarily optimized RT, which is key to predicting optimal efficacy in vivo.
Assuntos
Agonistas de Aminoácidos Excitatórios/farmacologia , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/agonistas , Triazóis/farmacologia , Regulação Alostérica , Animais , Células CHO , Cricetulus , Agonistas de Aminoácidos Excitatórios/síntese química , Cinética , Piperidinas/farmacologia , Piridinas/síntese química , Ratos Sprague-Dawley , Sono REM/efeitos dos fármacos , Relação Estrutura-Atividade , Triazóis/síntese química , TrítioRESUMO
BACKGROUND AND PURPOSE: Allosteric modulation of the mGlu2 receptor is a potential strategy for treatment of various neurological and psychiatric disorders. Here, we describe the in vitro characterization of the mGlu2 positive allosteric modulator (PAM) JNJ-46281222 and its radiolabelled counterpart [(3) H]-JNJ-46281222. Using this novel tool, we also describe the allosteric effect of orthosteric glutamate binding and the presence of a bound G protein on PAM binding and use computational approaches to further investigate the binding mode. EXPERIMENTAL APPROACH: We have used radioligand binding studies, functional assays, site-directed mutagenesis, homology modelling and molecular dynamics to study the binding of JNJ-46281222. KEY RESULTS: JNJ-46281222 is an mGlu2 -selective, highly potent PAM with nanomolar affinity (KD = 1.7 nM). Binding of [(3) H]-JNJ-46281222 was increased by the presence of glutamate and greatly reduced by the presence of GTP, indicating the preference for a G protein bound state of the receptor for PAM binding. Its allosteric binding site was visualized and analysed by a computational docking and molecular dynamics study. The simulations revealed amino acid movements in regions expected to be important for activation. The binding mode was supported by [(3) H]-JNJ-46281222 binding experiments on mutant receptors. CONCLUSION AND IMPLICATIONS: Our results obtained with JNJ-46281222 in unlabelled and tritiated form further contribute to our understanding of mGlu2 allosteric modulation. The computational simulations and mutagenesis provide a plausible binding mode with indications of how the ligand permits allosteric activation. This study is therefore of interest for mGlu2 and class C receptor drug discovery.
Assuntos
Piperidinas/farmacologia , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/metabolismo , Triazóis/farmacologia , Regulação Alostérica/efeitos dos fármacos , Animais , Células CHO , Cricetulus , Humanos , Modelos Moleculares , Receptores de Glutamato Metabotrópico/genéticaRESUMO
Positive allosteric modulators of the metabotropic glutamate 2 receptor have generated great interest in the past decade. There is mounting evidence of their potential as therapeutic agents in the treatment of multiple central nervous system disorders. We have previously reported substantial efforts leading to potent and selective mGlu2 PAMs. However, finding compounds with the optimal combination of in vitro potency and good druglike properties has remained elusive, in part because of the hydrophobic nature of the allosteric binding site. Herein, we report on the lead optimization process to overcome the poor solubility inherent to the advanced lead 6. Initial prototypes already showed significant improvements in solubility while retaining good functional activity but displayed new liabilities associated with metabolism and hERG inhibition. Subsequent subtle modifications efficiently addressed those issues leading to the identification of compound 27 (JNJ-46356479). This new lead represents a more balanced profile that offers a significant improvement on the druglike attributes compared to previously reported leads.
Assuntos
Piridinas/química , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/agonistas , Triazóis/química , Triazóis/farmacologia , Administração Oral , Regulação Alostérica/efeitos dos fármacos , Animais , Células CHO , Células CACO-2 , Cricetulus , Cães , Humanos , Masculino , Modelos Moleculares , Piridinas/administração & dosagem , Piridinas/farmacocinética , Ratos , Receptores de Glutamato Metabotrópico/metabolismo , Triazóis/administração & dosagem , Triazóis/farmacocinéticaRESUMO
Two QSAR approaches were applied to assist the design and to prioritise the synthesis of new active mGlu2 receptor positive allosteric modulators (PAMs). With the aim to explore a particular point of substitution the models successfully prioritised molecules originating from chemistry ideas and a large virtual library. The two methods, 3D topomer CoMFA and support vector machines with 2D ECFP6 fingerprints, delivered good correlation and success in this prospective application. Fourteen molecules with different substituent decoration were identified by the in silico models and synthesised. They were found to be highly active and their mGlu2 receptor PAM activity (pEC50) was predicted within 0.3 and 0.4log units of error with the two methods. The value of the molecules and the models for the future of the project is discussed.
Assuntos
Piridinas/química , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Triazóis/química , Regulação Alostérica , Desenho de Fármacos , Guanosina 5'-O-(3-Tiotrifosfato)/química , Humanos , Modelos Moleculares , Ligação Proteica , Relação Quantitativa Estrutura-Atividade , Receptores de Glutamato Metabotrópico/químicaRESUMO
We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of 5. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound 36 (JNJ-40411813). Full in vitro and in vivo profiles indicate that 36 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound 36 has been investigated in the clinic for schizophrenia and anxious depression disorders.
Assuntos
Ansiolíticos/química , Antipsicóticos/química , Piperidinas/química , Piridonas/química , Receptores de Glutamato Metabotrópico/metabolismo , Regulação Alostérica , Animais , Ansiolíticos/síntese química , Ansiolíticos/farmacologia , Antipsicóticos/síntese química , Antipsicóticos/farmacologia , Células CHO , Cricetulus , Cães , Canal de Potássio ERG1 , Eletroencefalografia , Canais de Potássio Éter-A-Go-Go/fisiologia , Células HEK293 , Humanos , Masculino , Técnicas de Patch-Clamp , Piperidinas/síntese química , Piperidinas/farmacologia , Piridonas/síntese química , Piridonas/farmacologia , Ensaio Radioligante , Ratos Sprague-Dawley , Sono/efeitos dos fármacos , Relação Estrutura-Atividade , Vigília/efeitos dos fármacosRESUMO
INTRODUCTION: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic glutamate receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology. Preferentially expressed on presynaptic nerve terminals, the mGlu2 receptor negatively modulates glutamate and GABA release and is widely distributed in the brain. High levels of mGlu2 receptors are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where glutamate hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia. Given the promise offered by mGlu2/3 receptor activation, there is increased interest in identifying small molecules which activate the receptor. A preferred approach is via positive allosteric modulators (PAMs) which bind at an alternative site to agonists. AREAS COVERED: This review covers the patent applications which were published between April 2009 and December 2012 on PAMs of the mGlu2, and it is a continuation of an earlier review published in this journal. EXPERT OPINION: Advances in medicinal chemistry and pharmacology have set the stage in the field of mGlu2 receptor PAMs. Compounds currently advancing in clinical trials will soon establish the therapeutic potential of this allosteric approach.
Assuntos
Encéfalo/metabolismo , Desenho de Fármacos , Receptores de Glutamato Metabotrópico/efeitos dos fármacos , Regulação Alostérica/efeitos dos fármacos , Animais , Sítios de Ligação , Encéfalo/fisiopatologia , Ácido Glutâmico/metabolismo , Humanos , Patentes como Assunto , Receptores de Glutamato Metabotrópico/metabolismo , Ácido gama-Aminobutírico/metabolismoRESUMO
The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines, which were conveniently radiolabeled with carbon-11, as potential positron emission tomography (PET) radiotracers for in vivo imaging of the allosteric binding site of the metabotropic glutamate (mGlu) receptor subtype 2 are described. The synthesized compounds proved to be potent and selective positive allosteric modulators (PAMs) of the mGlu receptor 2 (mGluR2) in a [³5S]GTPγS binding assay and were able to displace an mGluR2 PAM radioligand, which we had previously developed, with IC50 values in the low nanomolar range. The most promising candidates were radiolabeled and subjected to biodistribution studies and radiometabolite analysis in rats. Preliminary small-animal PET (µPET) studies in rats indicated that [¹¹C]20f binds specifically and reversibly to an mGluR2 allosteric site, strongly suggesting that it is a promising candidate for PET imaging of mGluR2 in the brain.
Assuntos
Piridinas/síntese química , Compostos Radiofarmacêuticos/síntese química , Receptores de Glutamato Metabotrópico/metabolismo , Tiazóis/síntese química , Regulação Alostérica , Sítio Alostérico , Animais , Ligação Competitiva , Encéfalo/metabolismo , Células CHO , Radioisótopos de Carbono , Cricetinae , Cricetulus , Humanos , Masculino , Tomografia por Emissão de Pósitrons , Piridinas/farmacocinética , Piridinas/farmacologia , Ensaio Radioligante , Compostos Radiofarmacêuticos/farmacocinética , Compostos Radiofarmacêuticos/farmacologia , Ratos , Ratos Wistar , Tiazóis/farmacocinética , Tiazóis/farmacologia , Distribuição TecidualRESUMO
Advanced leads from a series of 1,2,4-triazolo[4,3-a]pyridines with mGlu2 receptor PAM activity are reported. By modification of the analogous imidazo[1,2-a]pyridine series, the newly reported leads have improved potency, in vitro ADMET, and hERG as well as good in vivo PK profile. The optimization of the series focused on improving metabolic stability while controlling lipophilicity by introducing small modifications to the scaffold substituents. Analysis of this series combined with our previously reported mGlu2 receptor PAMs showed how lipophilic ligand efficiency was improved during the course of the program. Among the best compounds, example 20 (JNJ-42153605) showed a central in vivo efficacy by inhibition of REM sleep state at a dose of 3 mg/kg po in the rat sleep-wake EEG paradigm, a phenomenon shown earlier to be mGlu2 mediated. In mice, compound 20 reversed PCP-induced hyperlocomotion with an ED50 of 5.4 mg/kg sc, indicative of antipsychotic activity.
Assuntos
Antipsicóticos/síntese química , Piridinas/síntese química , Receptores de Glutamato Metabotrópico/metabolismo , Triazinas/síntese química , Regulação Alostérica , Animais , Antipsicóticos/farmacocinética , Antipsicóticos/farmacologia , Barreira Hematoencefálica/metabolismo , Linhagem Celular , Canal de Potássio ERG1 , Eletroencefalografia , Canais de Potássio Éter-A-Go-Go/antagonistas & inibidores , Humanos , Hipercinese/tratamento farmacológico , Masculino , Camundongos , Microssomos Hepáticos/metabolismo , Técnicas de Patch-Clamp , Polissonografia , Piridinas/farmacocinética , Piridinas/farmacologia , Ratos , Ratos Sprague-Dawley , Sono/efeitos dos fármacos , Relação Estrutura-Atividade , Triazinas/farmacocinética , Triazinas/farmacologia , Vigília/efeitos dos fármacosRESUMO
Advanced leads of an imidazopyridine series of positive allosteric modulators of the metabotropic glutamate 2 (mGlu2) receptor are reported. The optimization of in vitro ADMET and in vivo pharmacokinetic properties led to the identification of 27o. With good potency and selectivity for the mGlu2 receptor, 27o affected sleep-wake architecture in rats after oral treatment, which we have previously shown to be indicative of mGlu2 receptor-mediated central activity.
Assuntos
Compostos Bicíclicos Heterocíclicos com Pontes/síntese química , Imidazóis/síntese química , Indóis/síntese química , Piridinas/síntese química , Receptores de Glutamato Metabotrópico/metabolismo , Administração Oral , Regulação Alostérica , Animais , Disponibilidade Biológica , Encéfalo/metabolismo , Compostos Bicíclicos Heterocíclicos com Pontes/farmacocinética , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Linhagem Celular , Cricetinae , Cricetulus , Inibidores das Enzimas do Citocromo P-450 , Humanos , Imidazóis/farmacocinética , Imidazóis/farmacologia , Indóis/farmacocinética , Indóis/farmacologia , Canais Iônicos/antagonistas & inibidores , Masculino , Camundongos , Microssomos Hepáticos/metabolismo , Piridinas/farmacocinética , Piridinas/farmacologia , Ensaio Radioligante , Ratos , Receptores de Glutamato Metabotrópico/agonistas , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Sono/efeitos dos fármacos , Relação Estrutura-Atividade , Vigília/efeitos dos fármacosRESUMO
The discovery and characterization of compound 48, a selective and in vivo active mGlu2 receptor positive allosteric modulator (PAM), are described. A key to the discovery was the rational exploration of the initial HTS hit 13 guided by an overlay model built with reported mGlu2 receptor PAM chemotypes. The initial weak in vitro activity of the hit 13 was quickly improved, although compounds still had suboptimal druglike properties. Subsequent modulation of the physicochemical properties resulted in compounds having a more balanced profile, combining good potency and in vivo pharmacokinetic properties. Final refinement by addressing cardiovascular safety liabilities led to the discovery of compound 48. Besides good potency, selectivity, and ADME properties, compound 48 displayed robust in vivo activity in a sleep-wake electroencephalogram (sw-EEG) assay consistent with mGlu2 receptor activation, in accordance with previous work from our laboratories.
Assuntos
Nitrilas/síntese química , Piridonas/síntese química , Receptores de Glutamato Metabotrópico/agonistas , Regulação Alostérica , Animais , Encéfalo/metabolismo , Sinergismo Farmacológico , Canal de Potássio ERG1 , Eletroencefalografia , Canais de Potássio Éter-A-Go-Go/fisiologia , Células HEK293 , Humanos , Isomerismo , Camundongos , Nitrilas/farmacocinética , Nitrilas/farmacologia , Técnicas de Patch-Clamp , Piridonas/farmacocinética , Piridonas/farmacologia , Ratos , Receptores de Glutamato Metabotrópico/metabolismo , Sono REM/efeitos dos fármacos , Relação Estrutura-Atividade , VigíliaRESUMO
A series of 1,5-disubstituted pyridones was identified as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 2 (mGluR2) via high throughput screening (HTS). Subsequent SAR exploration led to the identification of several compounds with improved in vitro activity. Lead compound 8 was further profiled and found to attenuate the increase in PCP induced locomotor activity in mice.
Assuntos
Aminoácidos/farmacologia , Compostos Bicíclicos com Pontes/farmacologia , Agonistas de Aminoácidos Excitatórios/farmacologia , Piridinas/farmacologia , Piridonas/farmacologia , Receptores de Glutamato Metabotrópico/agonistas , Sulfonamidas/farmacologia , Regulação Alostérica , Aminoácidos/química , Animais , Compostos Bicíclicos com Pontes/química , Avaliação Pré-Clínica de Medicamentos , Estabilidade de Medicamentos , Agonistas de Aminoácidos Excitatórios/química , Agonistas de Aminoácidos Excitatórios/classificação , Humanos , Interações Hidrofóbicas e Hidrofílicas , Camundongos , Estrutura Molecular , Atividade Motora/efeitos dos fármacos , Piridinas/química , Piridonas/química , Piridonas/classificação , Piridonas/isolamento & purificação , Proteínas Recombinantes/efeitos dos fármacos , Relação Estrutura-Atividade , Sulfonamidas/químicaRESUMO
New synthesis approaches that have led to a series of novel tetrahydrodibenzo[b,f]furo[2,3-d]oxepin derivatives are described. According to preliminary data these novel tetracycles can be useful intermediates for the preparation of potential new therapeutic agents.